Category Archives: Corporate

Merck’s Frazier leads the way quitting Trump business council after Charlottesville; J&J’s Gorsky’s bail way too late.

The News: One day after J&J chief exec Alex Gorsky pub­licly com­mit­ted to stay­ing on Pres­i­dent Don­ald Trump’s man­u­fac­tur­ing coun­cil, he abruptly re­versed course–just as the sud­den mass departure of ex­ec­u­tives forced… Read more »

Centene rescuing Obamacare as just two US counties still lack insurers for 2018.

The News: Centene Corp. (St. Louis MO) on Tuesday (August 15, 2017) said it will sell Obamacare plans in Nevada’s remaining 14 “bare” counties in 2018. The insurer previously announced… Read more »

Zynerba sinks twice as cannabis trials flop; strike three looms, so where’s the Ouija board?

The News: Zynerba Pharmaceuticals Inc. (ZYNE) lost more than half its value last week to $7.03 after the drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage… Read more »

Kite submits IND for CAR-T multiple myeloma treatment; Novartis keeping wary eye on rival’s latest move in high-stakes race.

The News: Kite Pharma Inc. (Santa Monica CA) said it has submitted to the FDA an Investigational New Drug (IND) application to launch a Phase 1, first-in-human trial of a… Read more »

Endo coming out of the darkness into the light; contrarians, buy this name.

The News: Endo International Plc (Dublin IRL) on Tuesday (August 8, 2017) lowered its full-year revenue forecast, saying it expected lower sales of branded drugs to add to the pricing… Read more »

Teva stock crashes on 2Q earnings disaster; run for the hills, or buy at fire sale price?

The News: Teva Pharmaceutical Industries Ltd., which has been without a permanent CEO for six months, plunged $11.74, or 36% last week, to $20.60–the most in almost two decades. The… Read more »

Biogen’s poster presentation for Alzheimer’s candidate hardly noticed at London AAIC meeting as market focuses on quarterly results instead; start accumulating.

Biogen Inc. (Cambridge MA) laid out long-term plans to strengthen its core multiple sclerosis (MS) business, develop more neuroscience drugs and shop for late-stage assets, after reporting robust second-quarter results,… Read more »

UnitedHealthcare 2nd quarter sparkles; but time to figure out how Centene, Molina exploit Medicaid?

The News: UnitedHealth Group Inc.’s (Minnetonka MN) second-quarter earnings jumped 11% to beat analysts’ expectations even though the nation’s largest health insurer took a bigger hit than expected from coverage… Read more »

IPO breakout starts summer off with a bang; but two new issues fizzle.

It was certainly an off week (June 26 to 30, 2017) to for healthcare stocks, with the Nasdaq Healthcare Index (IXHC) giving back 2% to 732.05 after hitting an all-time… Read more »

Rx Hall of Shame Update: Former Insys employee pleads guilty in US opioid drug probe; case against ex CEO Michael Babich, others, in pre-trial mode.

The News: A former employee of Insys Therapeutics Inc. (Chandler AZ) pleaded guilty last week to having conspired to defraud insurers into paying for an expensive fentanyl-based drug that is… Read more »